Meghana Keshavan

Meghana Keshavan

Meghana has spent the last year-and-a-half writing about biotech and healthcare for the San Diego Business Journal. Previously, she's worked for Reuters, Crain’s Detroit Business, the Detroit Free Press and WDET, a Detroit-based National Public Radio affiliate. Meghana studied biochemistry and molecular biology at Penn State University and spent five years as a self-described "research peon in a schizophrenia genetics lab."

Follow Meghana Keshavan: Twitter |


Here are the private sector folks that are helping shape Obama’s Precision Medicine Initiative

Here are the private sector folks that are helping shape Obama’s Precision Medicine Initiative

March 30, 2015 6:52 pm by | 0 Comments

Looks like Obama has appointed quite the A-team to help the Precision Medicine Initiative shapeshift into something with some actual… shape. The $215 million initiative was first discussed at a two-day workshop mid-February that…


One test to screen them all: Entopsis using AI to build low-cost diagnostic for multiple diseases

One test to screen them all: Entopsis using AI to build low-cost diagnostic for multiple diseases

March 30, 2015 4:52 pm by | 0 Comments

With the majority of diagnostics out there, you need to know what you’re testing for: A strep throat screener won’t tell you that you have breast cancer. However, that’s how many asymptomatic, but…



Saphena Medical raising Series B round for its endoscopic vein harvesting device

Saphena Medical raising Series B round for its endoscopic vein harvesting device

March 27, 2015 6:18 pm by | 0 Comments

Boston startup Saphena Medical is kicking off a Series B round for its endoscopic vein harvesting device. The startup launched last year with $3 million in Series A funding, which it said…


A 3D printed, keratin-infused burn dressing: North Carolina startup gets $1.7M

A 3D printed, keratin-infused burn dressing: North Carolina startup gets $1.7M

March 27, 2015 1:34 pm by | 0 Comments

Keratins are an important class of proteins that help the body’s natural healing process – promoting soft and hard tissue repair and regeneration. KeraNetics, a North Carolina-based advanced biomaterials company, is…


White House unleashing five-year plan to fight superbugs; critics already finding weaknesses in approach

White House unleashing five-year plan to fight superbugs; critics already finding weaknesses in approach

March 26, 2015 6:56 pm by | 3 Comments

The White House on Friday will announce a new, five-year plan to curb the spread of antibiotic resistant microbes, Reuters reports – having reviewed a leaked copy of the 60-page document. However,…


Flagship Ventures raises $537M in new fund; plans to launch 5 companies per year

Flagship Ventures raises $537M in new fund; plans to launch 5 companies per year

March 26, 2015 9:48 am by | 0 Comments

Cambridge-based firm Flagship Ventures plans to launch as many as five new companies per year with its new, $537 million – its fifth, and the largest since its founding in…


Copper kills germs! Startup’s copper spray aimed at reducing hospital-acquired infections

Copper kills germs! Startup’s copper spray aimed at reducing hospital-acquired infections

March 26, 2015 8:30 am by | 0 Comments

It’s long been established that copper works as an effective antimicrobial – but it’s still a costly proposition to make every doorknob, keyboard and toilet seat out of the ubiquitous metal. San Diego-area…



Janssen regulatory director on CROs: “They’ll screw you in a heartbeat”

Janssen regulatory director on CROs: “They’ll screw you in a heartbeat”

March 25, 2015 8:08 pm by | 7 Comments

Some candor from the director of global regulatory affairs at Janssen Research & Development, as she touched on contracting with CROs: “They’ll screw you in a heartbeat.” Clinical research organizations are a fine option…


Stealth neuroscience startup Ovid Therapeutics raises $5M for… Angelman Syndrome? Stay tuned!

Stealth neuroscience startup Ovid Therapeutics raises $5M for… Angelman Syndrome? Stay tuned!

March 25, 2015 3:25 pm by | 0 Comments

Stealth New York-based startup Ovid Therapeutics just raised $5 million, according to a regulatory filing. CEO Matthew During, an accomplished neuroscientist, declined to comment on the fundraise, though he told me…


Biotech is booming for everyone but the employees

Biotech is booming for everyone but the employees

March 25, 2015 8:20 am by | 0 Comments

Here’s some advice: If you’re going to work for a biotech, ask for more stock options. The Timmerman Report is among those who recently put into focus what a few analysts have…


T3D Therapeutics’ drug explores the link between diabetes and Alzheimer’s disease

T3D Therapeutics’ drug explores the link between diabetes and Alzheimer’s disease

March 24, 2015 5:26 pm by | 0 Comments

There’s a growing consensus that two of society’s most rampant public health issues – Type II Diabetes and Alzheimer’s disease – are intertwined. It’s not all about clearing plaques anymore: Insulin modulation is…


Startup’s device uses targeted radiation – brachytherapy – to treat macular degeneration

Startup’s device uses targeted radiation – brachytherapy – to treat macular degeneration

March 24, 2015 2:28 pm by | 0 Comments

One of the most commonly prescribed drugs for wet age-related macular degeneration is Avastin – a cancer drug. So it’s not that surprising that a new approach for wet AMD…


Boston Scientific backs startup’s chronic venous insufficiency treatment in $5.9M Series A

Boston Scientific backs startup’s chronic venous insufficiency treatment in $5.9M Series A

March 23, 2015 5:28 pm by | 1 Comments

If veins in the legs don’t work properly, it can be difficult for blood to return to the heart. Blood can start to pool in the legs and lead to…


Emory spinout has topical rosacea therapy in the works

Emory spinout has topical rosacea therapy in the works

March 23, 2015 4:45 pm by | 0 Comments

Rosacea is common – it impacts 16 million Americans alone – but there’s no cure for the skin reddening, pimples and bumps characteristic of the disorder. Atlanta startup Accuitis Pharmaceuticals is developing…


Why clinical trial recruitment is so hard, and one solution: Patient education

Why clinical trial recruitment is so hard, and one solution: Patient education

March 23, 2015 2:06 pm by | 1 Comments

Clinical trials are the lifeblood of the life sciences industry – yet less than 5 percent of adult cancer patients will pursue experimental therapies. The biggest reason for this? Fear: “Although the…